MultiPlan Newsroom

Piper Sandler Maintains MultiPlan(MPLN.US) With Hold Rating, Cuts Target Price to $10

Moomoo NewsNov 6 07:31 ET

Piper Sandler Maintains MultiPlan(MPLN.US) With Hold Rating, Maintains Target Price $40

Moomoo NewsOct 18 07:31 ET

Citi Maintains MultiPlan(MPLN.US) With Hold Rating, Cuts Target Price to $10

Moomoo NewsSep 24 08:31 ET

MultiPlan Analyst Ratings

BenzingaSep 23 18:04 ET

Citigroup Maintains Neutral on MultiPlan, Lowers Price Target to $10

BenzingaSep 23 18:03 ET

MultiPlan Price Target Cut to $1.00/Share From $2.00 by Piper Sandler

Dow JonesAug 7 08:51 ET

MultiPlan Analyst Ratings

BenzingaAug 7 08:40 ET

Analysts Conflicted on These Healthcare Names: Nyxoah (NYXH), MultiPlan (MPLN) and Beam Therapeutics (BEAM)

TipRanksAug 7 07:10 ET

MultiPlan Analyst Ratings

BenzingaJun 26 06:03 ET

Barclays Sticks to Its Hold Rating for MultiPlan (MPLN)

TipRanksMar 1, 2023 03:21 ET

Barclays Adjusts Price Target on MultiPlan to $1 From $3, Maintains Equal-Weight Rating

MT NewswiresJan 18, 2023 20:55 ET

Goldman Sachs Adjusts Price Target on MultiPlan to $2.05 From $5.50, Maintains Neutral Rating

MT NewswiresNov 16, 2022 10:09 ET

Goldman Sachs Maintains Neutral on MultiPlan, Lowers Price Target to $2.05

Benzinga Real-time NewsNov 16, 2022 07:58 ET

MultiPlan Price Target Announced at $6.50/Share by Goldman Sachs

Dow JonesJul 12, 2022 06:20 ET

MultiPlan Initiated at Neutral by Goldman Sachs

Dow JonesJul 12, 2022 06:20 ET

Goldman Sachs Starts MultiPlan at Neutral With $6.50 Price Target

MT NewswiresJul 12, 2022 06:12 ET

Goldman Sachs Initiates Coverage On MultiPlan with Neutral Rating, Announces Price Target of $6.5

Benzinga Real-time NewsJul 12, 2022 06:10 ET